https://www.selleckchem.com/pr....oducts/ll37-human.ht
After a median of 9.3months of follow-up, the median PFS was 9.3months versus 4.4months, and the median OS was not estimable yet versus 12months for Child-Pugh A versus B patients, respectively. Prior nivolumab failure was the only significant factor associated with poorer PFS (HR = 3.253, p = 0.004). Child-Pugh class B (HR = 2.646, p = 0.039) and prior nivolumab failure (HR = 3.340, p = 0.014) were independent factors for poorer OS in multivariate analysis. A high DCR was observed by lenvatinib/pembrolizumab combination without adve
Like
Comment
Share
